Evidence map›Paper›PMID 31759888›Full record

ArticleClinical lung cancer2020

Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities.

Abbie Begnaud, Ping Yang, Camille Robichaux, Nathan Rubin, Robert Kratzke, Anne Melzer, Constantin Aliferis, Pamala Jacobson

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Clinical lung cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Abbie BegnaudDepartment of Medicine, University of Minnesota, Minneapolis, MN.
Ping YangDepartments of Internal Medicine and Medical Genetics, Mayo Clinic, Scottsdale, AZ.
Camille RobichauxDepartment of Medicine, University of Minnesota, Minneapolis, MN. Electronic address: robic020@umn.edu.
Nathan RubinBiostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
Robert KratzkeDepartment of Medicine, University of Minnesota, Minneapolis, MN.
Anne MelzerSection of Pulmonary and Critical Care, Minneapolis VA Healthcare System, Minneapolis, MN.
Constantin AliferisDepartment of Medicine, University of Minnesota, Minneapolis, MN.
Pamala JacobsonExperimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN.
University of Minnesota · USMayo Clinic in Arizona · USMinneapolis VA Health Care System · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
NCATS NIH HHS UL1 TR002494
6 · The paper itself

Abstract

backgroundAmerican Indians and Alaska Natives (AI/AN) continue to experience extreme lung cancer health disparities. The state of Minnesota is home to over 70,000 AI/AN, and this population has a 2-fold increase in lung cancer mortality compared to other races within Minnesota. Genetic mutation testing in lung cancer is now a standard of high-quality lung cancer care, and EGFR mutation testing has been recommended for all adenocarcinoma lung cases, regardless of smoking status. However, genetic testing is a controversial topic for some AI/AN. PATIENTS AND

methodsWe performed a multisite retrospective chart review funded by the Minnesota Precision Medicine Grand Challenge as a demonstration project to examine lung cancer health disparities in AI/AN. We sought to measure epidemiology of lung cancer among AI receiving diagnosis or treatment in Minnesota cancer referral centers as well as rate of EGFR testing. The primary outcome was the rate of EGFR mutational analysis testing among cases and controls with nonsquamous, non-small-cell lung cancer. We secured collaborations with 5 health care systems covering a diverse geographic and demographic population.

resultsWe identified 200 cases and 164 matched controls from these sites. Controls were matched on histology, smoking status, sex, and age. In both groups, about one third of subjects with adenocarcinoma received genetic mutation testing.

conclusionThere was no significant difference in mutation testing in AI compared to non-AI controls at large health care systems in Minnesota. These data indicate that other factors are likely contributing to the higher mortality in this group.

Indexed as

Health Status DisparitiesAdenocarcinoma of LungAgedAmerican Indian or Alaska NativeAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellFemaleFollow-Up StudiesGenetic TestingHumansLung NeoplasmsMaleMolecular Targeted TherapyPrognosisRegistriesGuideline adherenceHealth disparitiesInformaticsLung cancer mutationNSCLC

Identifiers

PMID31759888
PMCPMC7769592
OpenAlexW2982597691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.